Products
Sotiburafusp Biosimilar Antibody Fusion Protein (VEGFR1) for Research
Cat No.: GMP-Bios-INN-1397
Anti-VEGFR-1 therapeutic antibody (Pre-made Sotiburafusp biosimilar,Fusion Protein (whole mAb with protein)) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Sotiburafusp (development code HB-0025) is an antibody fusion protein in which the extracellular domain of human vascular endothelial growth factor receptor 1 (VEGFR-1) is fused to a humanized immunoglobulin heavy chain. It is developed by Huabo Biopharm for renal cell carcinoma and solid tumours in Phase II development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1397-1mg | 1mg | 3090 |
| GMP-Bios-INN-1397-10mg | 10mg | |
| GMP-Bios-INN-1397-100mg | 100mg | |
| GMP-Bios-INN-1397-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Sotiburafusp biosimilar, Fusion Protein (whole mAb with protein) targeting VEGFR-1: Recombinant therapeutic protein targeting VEGFR-1/FLT-1/VEGFR1/FLT1 |
| INN Name | Sotiburafusp |
| Target | VEGFR-1 |
| Format | Fusion Protein (whole mAb with protein) |
| Derivation | na |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2023 |
| Year Recommended | 2023 |
| Companies | Huabo Biopharm |
| Conditions Approved | na |
| Conditions Active | Renal cell carcinoma;Solid tumours |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
